Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Rectal Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Melanoma 1Medulloblastoma 1Familial ependymoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Melanoma × Semaxinib × Clear all
NCT00006003 2013-01-24

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

National Cancer Institute (NCI)

Phase 2 Terminated
35 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡